HealthStream (HSTM) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The 2025 Annual Meeting will be held virtually on May 29, 2025, with shareholders voting on director elections, auditor ratification, and executive compensation approval.
Shareholders of record as of March 31, 2025, are entitled to vote, with 30,525,266 shares outstanding.
The Board recommends voting in favor of all proposals, including the election of three Class I directors, ratification of Ernst & Young LLP as auditor, and approval of executive compensation.
Voting matters and shareholder proposals
Proposals include electing three Class I directors, ratifying Ernst & Young LLP as auditor, and an advisory vote on executive compensation.
No other shareholder proposals were received by the deadline; any other business will be handled at the discretion of the meeting's designated officers.
Shareholders may submit proposals for the 2026 meeting by December 11, 2025, and director nominations between January 29 and February 28, 2026.
Board of directors and corporate governance
The Board consists of ten members divided into three classes, with regular skills assessments and annual evaluations.
All standing committees (Audit, Compensation, Nominating and Corporate Governance) are composed solely of independent directors.
The Lead Independent Director has significant authority, including presiding over executive sessions and serving as a liaison between independent directors and management.
Board diversity includes three female members and one member of Middle Eastern ethnicity.
Directors are encouraged to attend all meetings, and all attended 100% of meetings in 2024.
Latest events from HealthStream
- Record 2025 revenue and EBITDA growth, with 2026 guidance projecting further expansion.HSTM
Q4 202513 Mar 2026 - Q2 2024 revenue up 3.4% to $71.6M, guidance reaffirmed, and SaaS platform growth continues.HSTM
Q2 20243 Feb 2026 - Record Q3 revenue, profit growth, and raised guidance highlight strong operational momentum.HSTM
Q3 202419 Jan 2026 - Strong SaaS growth, acquisitions, and platform innovation drive robust 2024 results and 2025 outlook.HSTM
Q4 202423 Dec 2025 - Annual meeting to address director elections, pay, and auditor ratification.HSTM
Proxy Filing1 Dec 2025 - Record Q2 2025 revenue, profit growth, and a $25M share buyback highlight strong results.HSTM
Q2 202523 Nov 2025 - Revenue up 1%, profit down 17%; guidance trimmed, but cash flow and bookings remain strong.HSTM
Q1 202519 Nov 2025 - Record Q3 revenue, strong cash, and strategic actions drive continued growth.HSTM
Q3 202513 Nov 2025